High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma

BACKGROUND: Renal cell carcinoma (RCC) responds to agents that inhibit vascular endothelial growth factor (VEGF) pathway. Sorafenib, a multikinase inhibitor of VEGF receptor, is effective at producing tumor responses and delaying median progression free survival in patients with cytokine refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoen, Zhang, Liang, Goldberg, S Nahum, Bhasin, Manoj, Brown, Victoria, Alsop, David C, Signoretti, Sabina, Mier, James W, Atkins, Michael B, Bhatt, Rupal S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258225/
https://www.ncbi.nlm.nih.gov/pubmed/22188900
http://dx.doi.org/10.1186/1479-5876-9-220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258225/
https://www.ncbi.nlm.nih.gov/pubmed/22188900
http://dx.doi.org/10.1186/1479-5876-9-220

Ejemplares similares